CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
67.2%−24.8 pts over 5 years
Operating margin
-429.5%−462.4 pts over 5 years
Net margin
398.4%+370.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +59.8% | -41.5% | -38.4% | +3.5% | |
| Gross profit | +60.6% | -41.4% | -42.2% | – | |
| Net income | +489.4% | – | +4.9% | – | |
| EPS, diluted | +472.0% | – | -2.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1778.4% | 68.5% | -473.5% | |
| Return on assets | -65.2% | 21.1% | 47.5% | |
| Current ratio | 2.86 | 5.27 | 1.47 | |
| Interest coverage | -14.5× | 7.4× | -20.1× | |
| Inventory turnover | – | 1.4× | 3.7× | |
| Capex to revenue | 3.4% | 1.5% | – | |
| Diluted shares | 42M | 83M | 117M |
Cash use needs five years of cash flow figures
Coherus Oncology does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin398.4%
×Asset turnover0.12×
×Equity multiplier-9.96×
=Return on equity, FY2025-473.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 398.4% | 0.12× | -9.96× | -473.5% |
| FY2024 | 108.0% | 0.05× | -3.31× | -17.5% |
| FY2023 | -92.5% | 0.46× | -3.36× | 143.8% |
| FY2022 | -138.2% | 0.36× | -29.23× | 1470.1% |
| FY2021 | -87.9% | 0.43× | 4.02× | -151.6% |
| FY2020 | 27.8% | 0.76× | 3.24× | 68.5% |
| FY2019 | 25.2% | 1.40× | 7.63× | 269.7% |
| FY2017 | -15306.6% | 0.01× | 6.68× | -932.9% |
| FY2016 | -67.0% | 0.97× | 27.30× | -1778.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$168.02M
- Cash generatingOperating cash flow above zero-$138.51M
- Return on assets improvedROA up on the prior year4.5% → 37.5%
- Earnings backed by cashOperating cash flow above net income-$138.51M vs $168.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.21 → 1.47
- No dilutionShare count did not rise115M → 117M
- Gross margin improvedGross margin up on the prior year66.93% → 67.24%
- More efficientAsset turnover rose0.04 → 0.09